Tags

Globally, Glaucoma is the second leading cause of blindness after cataract. In India, approximately 11 million people have lost their vision due to this incurable disease. Compliance is a major concern in treating Glaucoma as nearly 50% of patients admit non-continuous use of medications by 6 months after start of therapy. Multiple dosing limits patient’s adherence to the treatment and thereby, worsens the condition. Patients feel that the treatment of Glaucoma is inconvenient and interferes with their day-to-day life. Bausch+Lomb’s Travoflo is a convenient once-daily-dosing therapy for Glaucoma, which is aimed at improving patient compliance by reducing the number of interruptions and improving the overall outcome.